Investigational drug · Phase 3
F027
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes (T2DM).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "F027"
First trial start
2025
Aug 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "F027", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes (T2DM)
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "F027" as an intervention, largest first.
- Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 DiabetesPivotal-lookingNot yet recruiting
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT07046273 · 496 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 1, 2028
Drug: F027; Ozempic® · For: Type 2 Diabetes (T2DM)
Newest research
PubMed records naming it or its code names, newest first.
- Impacts of Maternal Bovine Appeasing Substance Administered at Weaning on Behavioral and Physiological Adaptation of Beef Heifers to the Feedlot.
Gellatly D, Lei Y, Neale A, et al. · Animals (Basel) 2025
- GWAS and RNA-seq reveal novel loci and genes of low-nitrogen tolerance in cucumber (Cucumis sativus L.).
Wu H, Yan H, Li B, et al. · Front Plant Sci 2025
- Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers.
Schroeder CP, Hengel RL, Nathan RV, et al. · Anaerobe 2022
- Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings.
Jo J, Gonzales-Luna AJ, Lancaster CK, et al. · Anaerobe 2022
- A new diketopiperazine from an endophytic fungus Aspergillus aculeatus F027.
Ma H, Wang F, Jin X, et al. · Nat Prod Res 2021
- In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.
Begum K, Bassères E, Miranda J, et al. · Antimicrob Agents Chemother 2020
Also in development for Type 2 Diabetes (T2DM)
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- BGM0504Phase 35 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- GZR101-80Phase 21 trial
Gan & Lee Pharmaceuticals. · Type 2 Diabetes (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.